This company is no longer in business. Investors can get details about any potential exits or failures here.

Stella Diagnostics

Stella Diagnostics

Early Stage

Optimizing Patient Management Strategies for Esophageal Diseases

Optimizing Patient Management Strategies for Esophageal Diseases

Overview

Raised to Date: Raised: $75,000

Total Commitments ($USD)

Platform

Dalmore Group

Start Date

06/23/2021

Close Date

Not Provided

Min. Goal
$5,000
Max. Goal
$20,000,000
Min. Investment

$5,000

Security Type

Equity - Preferred

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$5.00

Rolling Commitments ($USD)

Status
Funded
Reporting Date

06/04/2022

% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$220

# of Investors

1

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

1992

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Salt Lake City, Utah

Stella Diagnostics is raising funds on Dalmore Group through Reg A+ crowdfunding. It is a molecular diagnostics company that is focused on improving patient management strategies for people living with the severe oesophageal disease. Stella Diagnostics’ mass spectrometric proteomic assays will help physicians study the molecular properties of patients’ tissues to determine if the disease is stable, progressing, or cancerous. Joe Abdo founded Stella Diagnostics in 1992. The current crowdfunding campaign has no minimum target and a maximum target of $20,000,000. The campaign proceeds will be used for product research, development, infrastructure-related costs, and administrative costs.

Balance Sheet

Cash and Cash Equivalents

$37,473

Total Assets

$39,807

Accounts Payable & Accrued Liabilities

$905,027

Long Term Debt

$252,286

Total Liabilities

$10,585,028

Total Stockholders' Equity

$-10,545,221

Total Liabilities and Equity

$39,807

Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev

$164,846

Net Income

$-262,054

Earnings Per Share - Basic

$0.00

Earnings Per Share - Diluted

$0.00

Financials as of: 06/23/2021
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Stella Diagnostics on Dalmore Group 2022
Platform: Dalmore Group
Security Type: Equity - Preferred
Price per Share: $5.00

Follow company

Follow Stella Diagnostics on Dalmore Group 2022

Buy Stella Diagnostics's Deal Report

Warning: according to the close date for this deal, Stella Diagnostics may no longer be accepting investments.

Stella Diagnostics Deal Report

Get KingsCrowd’s comprehensive report on Stella Diagnostics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Stella Diagnostics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Stella Diagnostics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge